<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1506">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141552</url>
  </required_header>
  <id_info>
    <org_study_id>KY2021-162</org_study_id>
    <nct_id>NCT05141552</nct_id>
  </id_info>
  <brief_title>The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure</brief_title>
  <acronym>SDHF</acronym>
  <official_title>The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SGLT2 inhibitor is a new type of sugar-lowering medicine and is recommended to treat heart&#xD;
      failure. eGFR lower than 30ml/min/1.73M2 is contraindication of SGLT2 inhibitor. Heart&#xD;
      failure is one of the most frequency CVD events for hemodialysis patients. But hemodialysis&#xD;
      patient is unable to be treated with SGLT2 inhibitors as the contraindication. However,&#xD;
      solute and fluid clearance are dependent on dialysis, but not renal function in hemodialysis&#xD;
      patients. There is no data of SGLT2 inhibitor on hemodialysis patients. The aim of the&#xD;
      present study is evaluate the safety of Dapagliflozin in hemodialysis patients with heart&#xD;
      failure.&#xD;
&#xD;
      This is a randomized, control, open study. 20 hemodialysis patients with heart failure will&#xD;
      be recruited. 10 of 20 subjects will be treated with dapagliflozin 10mg everyday for 12&#xD;
      weeks. The primary outcome is a composite of numbers of hypoglycemia events, urinary&#xD;
      infection events and abnormal of laboratory results. The secondary outcomes is the changes of&#xD;
      NT-.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the safety of dapagliflozin in hemodialysis patients with heart failure is the main&#xD;
      purpose of this study. and Estimate the change of NT-proBNP is the secondary purpose.&#xD;
&#xD;
      This is a randomized, control and open study.&#xD;
&#xD;
      The including criteria are 1. Understand the present study and sign informed consert 2. Age&#xD;
      is between 18 and 70 3. 2 or 3 times blood purification treatments (inclusion hemodialysis,&#xD;
      hemofiltration, hemoperfusion) every week, 4. Blood purification treatment more than 3 month&#xD;
      5. Using AV fistula or artificial vascular access 6. With chronic heart failure (NYHC II-IV),&#xD;
      and NT-proBNP&gt;11500 or BNP&gt;500 7. ARNI or RAS inhibitor or Aldosterone inhibitors treatment&#xD;
      for at least 4 weeks with a stable dose The exclusion criteria are 1.Blood purification less&#xD;
      than 3 month 2.With fluid overload and URR&lt;50% 3.Have severe hypoglycemia (more than 2 events&#xD;
      with 4 weeks prior to sign concert information) 4.Have severe hypotension (blood pressure&#xD;
      &lt;90/60mmHg more than 3 times with 4 weeks prior to sign concert information) 5.Have acute&#xD;
      pulmonary edema 6.Have ketoacidosis 7.Have active pyelnephritis and symptomatic lower urinary&#xD;
      infection 8.Subject is pregnant , is breast feeding 9.Subject has known SGLT2 inhibitor&#xD;
      allergy or intolerance adverse reactions 10.Subject is currentluy enrolled in or has not yet&#xD;
      completed at least 30days since ending other investigational device or drug trials&#xD;
      11.Investigator believe subject is not suitable for this study&#xD;
&#xD;
      Subjects will divide into two groups. Dapa group will be treated with dapagliflozin 10mg qd&#xD;
      and standard anti-heart failure therapy. Control group will be treated with standard&#xD;
      anti-heart failure therapy.&#xD;
&#xD;
      The primary outcome is a composite of the number of hypoglycemia events, urinary tract&#xD;
      infection events and the abnormal laboratory results. The secondary outcome is the change of&#xD;
      NT-proBNP&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of dapagliflozin</measure>
    <time_frame>12 weeks</time_frame>
    <description>a composite of number of hypoglycemia events, urinary tract infection events and abnormal laboratory results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effective of dapagliflozin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of NT-proBNP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemodialysis Complication</condition>
  <arm_group>
    <arm_group_label>dapa group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be treated with dapagliflozin (10mg per day) and standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>subjects will be treated with standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Tab</intervention_name>
    <description>In both group, subjects keep blood purification and anti heart failure treatment, including ARNI, RASi, Aldosterone inhibitors and beta receptor blocker.</description>
    <arm_group_label>dapa group</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand the present studyAgree and sign informed consert&#xD;
&#xD;
          2. Age is between 18 and 70 Men or women ≧18 years and &lt;70 years of age at screening&#xD;
&#xD;
          3. Treated with maintenance blood purification 2 or 3 times blood purification treatments&#xD;
             (including hemodialysis, hemofiltration, hemoperfusion) every week2 or 3 times a week,&#xD;
&#xD;
          4. Blood purification treatment more than 3 month before randomization&#xD;
&#xD;
          5. Blood purification by uUsing AV fistula or artificial vascular access&#xD;
&#xD;
          6. DiagnosisWith chronic heart failure (NYHC II-IV), and NT-proBNP&gt;11500 or BNP&gt;500&#xD;
&#xD;
          7. ARNI or RAS inhibitor or Aldosterone inhibitors or beta receptor blocker treatment for&#xD;
             at least 4 weeks with a stable dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood purification less than 3 month&#xD;
&#xD;
          2. With fluid overload and URR&lt;50%&#xD;
&#xD;
          3. Have severe hypoglycemia (more than 2 events with 4 weeks prior to sign concert&#xD;
             information)&#xD;
&#xD;
          4. Have severe hypotension (blood pressure &lt;90/60mmHg more than 3 times with 4 weeks&#xD;
             prior to sign concert information)&#xD;
&#xD;
          5. Have acute pulmonary edema&#xD;
&#xD;
          6. Have ketoacidosis&#xD;
&#xD;
          7. Have active pyelnephritis and symptomatic lower urinary infection&#xD;
&#xD;
          8. Subject is pregnant , is breast feeding&#xD;
&#xD;
          9. Subject has known SGLT2 inhibitor allergy or intolerance adverse reactions&#xD;
&#xD;
         10. Subject is currentluy enrolled in or has not yet completed at least 30days since&#xD;
             ending other investigational device or drug trials&#xD;
&#xD;
         11. Investigator believe subject is not suitable for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leyi Gu</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leyi Gu</last_name>
    <email>guleyi@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xueping Huang</last_name>
    <phone>86-18101896182</phone>
  </overall_contact_backup>
  <results_reference>
    <citation>McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.</citation>
    <PMID>31535829</PMID>
  </results_reference>
  <results_reference>
    <citation>Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.</citation>
    <PMID>32865377</PMID>
  </results_reference>
  <results_reference>
    <citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Oct 14;:.</citation>
    <PMID>34447992</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh M, Kumar A. Risks Associated with SGLT2 Inhibitors: An Overview. Curr Drug Saf. 2018;13(2):84-91. doi: 10.2174/1574886313666180226103408. Review.</citation>
    <PMID>29485006</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Leyi Gu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

